×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
OTCMKTS:CCEL

Cryo-Cell International Stock Forecast, Price & News

$6.13
+0.21 (+3.55%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.02
$6.31
50-Day Range
$5.83
$6.58
52-Week Range
$5.83
$14.16
Volume
1,355 shs
Average Volume
6,875 shs
Market Capitalization
$51.82 million
P/E Ratio
23.56
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

CCEL Stock Forecast (MarketRank)

Overall MarketRank

1.26 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Cryo-Cell International logo

About Cryo-Cell International (OTCMKTS:CCEL)

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CCEL Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CCEL
Employees
83
Year Founded
N/A

Company Calendar

Last Earnings
4/13/2022
Today
6/28/2022
Fiscal Year End
11/30/2022

Profitability

Net Income
$2.08 million
Pretax Margin
9.61%

Debt

Sales & Book Value

Annual Sales
$28.89 million
Cash Flow
$0.40 per share
Book Value
$0.49 per share

Miscellaneous

Free Float
5,190,000
Market Cap
$51.82 million
Optionable
Not Optionable
Beta
0.58














Cryo-Cell International Frequently Asked Questions

How has Cryo-Cell International's stock performed in 2022?

Cryo-Cell International's stock was trading at $11.60 on January 1st, 2022. Since then, CCEL stock has decreased by 47.2% and is now trading at $6.1250.
View the best growth stocks for 2022 here
.

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International, Inc. (OTCMKTS:CCEL) posted its quarterly earnings results on Wednesday, April, 13th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $7.26 million for the quarter. Cryo-Cell International had a net margin of 7.59% and a trailing twelve-month return on equity of 51.59%.
View Cryo-Cell International's earnings history
.

Who are Cryo-Cell International's key executives?

Cryo-Cell International's management team includes the following people:
  • Mr. David I. Portnoy, Chairman & Co-CEO (Age 59, Pay $1.22M)
  • Mr. Mark L. Portnoy, Co-CEO & Director (Age 58, Pay $873.34k)
  • Ms. Jill M. Taymans, CFO & VP of Fin. (Age 52, Pay $205.42k)
  • Mr. Oleg Mikulinsky, Chief Information Officer (Age 49, Pay $326.35k)
  • Dr. Joanne Kurtzberg M.D., Medical Director and Member of Medical & Scientific Advisory Board

What other stocks do shareholders of Cryo-Cell International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryo-Cell International investors own include NVIDIA (NVDA), Overstock.com (OSTK), Avid Technology (AVID), Boeing (BA), Enphase Energy (ENPH), OPKO Health (OPK), Riot Blockchain (RIOT), Aldeyra Therapeutics (ALDX), Alimera Sciences (ALIM) and Allena Pharmaceuticals (ALNA).

What is Cryo-Cell International's stock symbol?

Cryo-Cell International trades on the OTCMKTS under the ticker symbol "CCEL."

Who are Cryo-Cell International's major shareholders?

Cryo-Cell International's stock is owned by many different retail and institutional investors. Top institutional shareholders include Iszo Capital Management LP (4.22%). Company insiders that own Cryo-Cell International stock include Brian L Sheehy, David Portnoy, George Gaines and Mark L Portnoy.
View institutional ownership trends for Cryo-Cell International
.

Which institutional investors are selling Cryo-Cell International stock?

CCEL stock was sold by a variety of institutional investors in the last quarter, including Iszo Capital Management LP.
View insider buying and selling activity for Cryo-Cell International
or view top insider-selling stocks.

How do I buy shares of Cryo-Cell International?

Shares of CCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cryo-Cell International's stock price today?

One share of CCEL stock can currently be purchased for approximately $6.13.

How much money does Cryo-Cell International make?

Cryo-Cell International (OTCMKTS:CCEL) has a market capitalization of $51.82 million and generates $28.89 million in revenue each year. The company earns $2.08 million in net income (profit) each year or $0.259990 on an earnings per share basis.

How many employees does Cryo-Cell International have?

Cryo-Cell International employs 83 workers across the globe.

How can I contact Cryo-Cell International?

Cryo-Cell International's mailing address is 700 Brooker Creek Boulevard Suite 1800, Oldsmar FL, 34677. The official website for Cryo-Cell International is www.cryo-cell.com. The company can be reached via phone at (813) 749-2100, via email at [email protected], or via fax at 813-855-4745.

This page (OTCMKTS:CCEL) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.